- /
- Supported exchanges
- / US
- / KROS.NASDAQ
Keros Therapeutics Inc (KROS NASDAQ) stock market data APIs
Keros Therapeutics Inc Financial Data Overview
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Keros Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Keros Therapeutics Inc data using free add-ons & libraries
Get Keros Therapeutics Inc Fundamental Data
Keros Therapeutics Inc Fundamental data includes:
- Net Revenue: 247 M
- EBITDA: 45 026 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -1.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Keros Therapeutics Inc News
New
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $1.41 per share a year ago. These f...
Keros Therapeutics Reports Third Quarter 2025 Financial Results
Keros Therapeutics, Inc. LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company foc...
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?
Keros Therapeutics, Inc. (KROS) shares ended the last trading session 9.8% higher at $15.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ses...
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares
* Keros Therapeutics (NASDAQ:KROS [https://seekingalpha.com/symbol/KROS]) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per sha...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.